{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T16:16:30Z","timestamp":1764260190894,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s40262-021-00990-7","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T01:02:46Z","timestamp":1616461366000},"page":"1015-1027","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effect of Kidney or Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Somapacitan: Two Open-Label, Parallel-Group Trials"],"prefix":"10.1007","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0036-8345","authenticated-orcid":false,"given":"Birgitte","family":"Bentz Damholt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah Louise","family":"Dombernowsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2403-3520","authenticated-orcid":false,"given":"Mette","family":"Dahl Bendtsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Bisgaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2210-0366","authenticated-orcid":false,"given":"Michael","family":"H\u00f8jby Rasmussen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,23]]},"reference":[{"issue":"6","key":"990_CR1","doi-asserted-by":"publisher","first-page":"C1","DOI":"10.1530\/EJE-16-0111","volume":"174","author":"JS Christiansen","year":"2016","unstructured":"Christiansen JS, Backeljauw PF, Bidlingmaier M, Biller BM, Boguszewski MC, Casanueva FF, et al. Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations. Eur J Endocrinol. 2016;174(6):C1-8.","journal-title":"Eur J Endocrinol."},{"issue":"4","key":"990_CR2","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/MED.0000000000000416","volume":"25","author":"KCJ Yuen","year":"2018","unstructured":"Yuen KCJ, Miller BS, Biller BMK. The current state of long-acting growth hormone preparations for growth hormone therapy. Curr Opin Endocrinol Diabetes Obes. 2018;25(4):267\u201373.","journal-title":"Curr Opin Endocrinol Diabetes Obes."},{"issue":"10","key":"990_CR3","doi-asserted-by":"publisher","first-page":"E1819","DOI":"10.1210\/jc.2014-1702","volume":"99","author":"MH Rasmussen","year":"2014","unstructured":"Rasmussen MH, Olsen MW, Alifrangis L, Klim S, Suntum M. A reversible albumin-binding growth hormone derivative is well tolerated and possesses a potential once-weekly treatment profile. J Clin Endocrinol Metab. 2014;99(10):E1819\u201329.","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"990_CR4","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/cen.13409","volume":"87","author":"T Battelino","year":"2017","unstructured":"Battelino T, Rasmussen MH, De Schepper J, Zuckerman-Levin N, Gucev Z, Savendahl L. Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: a randomized dose-escalation trial. Clin Endocrinol (Oxf). 2017;87(4):350\u20138.","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"4","key":"990_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/clinem\/dgaa049","volume":"105","author":"G Johannsson","year":"2020","unstructured":"Johannsson G, Gordon MB, Rasmussen MH, Holme Hakonsson I, Karges W, Svaerke C, et al. Once-weekly somapacitan is effective and well tolerated in adults with GH deficiency: a randomized phase 3 trial. J Clin Endocrinol Metab. 2020;105(4):1\u201319.","journal-title":"J Clin Endocrinol Metab."},{"key":"990_CR6","unstructured":"ClinicalTrials.gov. Sogroya Prescribing Information. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761156s000lbl.pdf. Accessed 12 Oct 2020."},{"issue":"3","key":"990_CR7","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1021\/js950412j","volume":"85","author":"P Kurtzhals","year":"1996","unstructured":"Kurtzhals P, Havelund S, Jonassen I, Kiehr B, Ribel U, Markussen J. Albumin binding and time action of acylated insulins in various species. J Pharm Sci. 1996;85(3):304\u20138.","journal-title":"J Pharm Sci."},{"issue":"9","key":"990_CR8","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1021\/jm9909645","volume":"43","author":"LB Knudsen","year":"2000","unstructured":"Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, Pedersen FZ, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem. 2000;43(9):1664\u20139.","journal-title":"J Med Chem."},{"issue":"18","key":"990_CR9","doi-asserted-by":"publisher","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","volume":"58","author":"J Lau","year":"2015","unstructured":"Lau J, Bloch P, Schaffer L, Pettersson I, Spetzler J, Kofoed J, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370\u201380.","journal-title":"J Med Chem."},{"issue":"3","key":"990_CR10","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1210\/jc.2015-1991","volume":"101","author":"MH Rasmussen","year":"2016","unstructured":"Rasmussen MH, Janukonyte J, Klose M, Marina D, Tanvig M, Nielsen LF, et al. Reversible albumin-binding GH possesses a potential once-weekly treatment profile in adult growth hormone deficiency. J Clin Endocrinol Metab. 2016;101(3):988\u201398.","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"990_CR11","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1172\/JCI117069","volume":"93","author":"D Haffner","year":"1994","unstructured":"Haffner D, Schaefer F, Girard J, Ritz E, Mehls O. Metabolic clearance of recombinant human growth hormone in health and chronic renal failure. J Clin Invest. 1994;93(3):1163\u201371.","journal-title":"J Clin Invest."},{"issue":"11","key":"990_CR12","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1111\/bph.13473","volume":"173","author":"A Thorsted","year":"2016","unstructured":"Thorsted A, Thygesen P, Agerso H, Laursen T, Kreilgaard M. Translational mixed-effects PKPD modelling of recombinant human growth hormone\u2014from hypophysectomized rat to patients. Br J Pharmacol. 2016;173(11):1742\u201355.","journal-title":"Br J Pharmacol."},{"key":"990_CR13","volume-title":"Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function","author":"European Medicines Agency","year":"2015","unstructured":"European Medicines Agency. Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function. Amsterdam: European Medicines Agency; 2015."},{"key":"990_CR14","unstructured":"European Medicines Agency; Committee for Medicinal Products for Human Use. Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function. Amsterdam; European Medicines Agency; 2005."},{"key":"990_CR15","unstructured":"US FDA; US Department of Health and Human Services. Guidance for Industry. Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling. Silver Spring: US FDA; 2003."},{"key":"990_CR16","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ghir.2017.05.006","volume":"35","author":"P Thygesen","year":"2017","unstructured":"Thygesen P, Andersen HS, Behrens C, Fels JJ, Norskov-Lauritsen L, Rischel C, et al. Nonclinical pharmacokinetic and pharmacodynamic characterisation of somapacitan: a reversible non-covalent albumin-binding growth hormone. Growth Horm IGF Res. 2017;35:8\u201316.","journal-title":"Growth Horm IGF Res."},{"issue":"5","key":"990_CR17","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1210\/jc.2013-3059","volume":"99","author":"M Bidlingmaier","year":"2014","unstructured":"Bidlingmaier M, Friedrich N, Emeny RT, Spranger J, Wolthers OD, Roswall J, et al. Reference intervals for insulin-like growth factor-1 (IGF-I) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. J Clin Endocrinol Metab. 2014;99(5):1712\u201321.","journal-title":"J Clin Endocrinol Metab."},{"issue":"20","key":"990_CR18","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191\u20134.","journal-title":"JAMA"},{"key":"990_CR19","unstructured":"International Conference on Harmonisation. ICH Harmonised Tripartite Guideline for Good Cinical Practice E6 (R2). 2016."},{"key":"990_CR20","unstructured":"Novo Nordisk Inc. Sogroya, somapacitan-beco injection Prescribing Information. Novo Nordisk Inc.; 2020."},{"issue":"1","key":"990_CR21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.krcp.2011.12.005","volume":"31","author":"Y Oh","year":"2012","unstructured":"Oh Y. The insulin-like growth factor system in chronic kidney disease: Pathophysiology and therapeutic opportunities. Kidney Res Clin Pract. 2012;31(1):26\u201337.","journal-title":"Kidney Res Clin Pract."},{"issue":"1","key":"990_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00467-007-0527-x","volume":"23","author":"S Mahesh","year":"2008","unstructured":"Mahesh S, Kaskel F. Growth hormone axis in chronic kidney disease. Pediatr Nephrol. 2008;23(1):41\u20138.","journal-title":"Pediatr Nephrol."},{"issue":"4","key":"990_CR23","first-page":"377","volume":"10","author":"H Jernstrom","year":"2001","unstructured":"Jernstrom H, Deal C, Wilkin F, Chu W, Tao Y, Majeed N, et al. Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomark Prev. 2001;10(4):377\u201384.","journal-title":"Cancer Epidemiol Biomark Prev."},{"key":"990_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1472-6874-11-15","volume":"11","author":"KM Blackmore","year":"2011","unstructured":"Blackmore KM, Wong J, Knight JA. A cross-sectional study of different patterns of oral contraceptive use among premenopausal women and circulating IGF-1: implications for disease risk. BMC Womens Health. 2011;11:15.","journal-title":"BMC Womens Health."},{"issue":"5","key":"990_CR25","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1053\/gast.1997.v113.pm9352864","volume":"113","author":"A Donaghy","year":"1997","unstructured":"Donaghy A, Ross R, Wicks C, Hughes SC, Holly J, Gimson A, Williams R. Growth hormone therapy in patients with cirrhosis: a pilot study of efficacy and safety. Gastroenterology. 1997;113(5):1617\u201322.","journal-title":"Gastroenterology"},{"issue":"4","key":"990_CR26","doi-asserted-by":"publisher","first-page":"233","DOI":"10.14740\/jocmr2761w","volume":"9","author":"RG de la Garza","year":"2017","unstructured":"de la Garza RG, Morales-Garza LA, Martin-Estal I, Castilla-Cortazar I. Insulin-like growth factor-1 deficiency and cirrhosis establishment. J Clin Med Res. 2017;9(4):233\u201347.","journal-title":"J Clin Med Res."},{"issue":"6","key":"990_CR27","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1210\/jcem.87.6.8548","volume":"87","author":"JD Wallace","year":"2002","unstructured":"Wallace JD, Abbott-Johnson WJ, Crawford DH, Barnard R, Potter JM, Cuneo RC. GH treatment in adults with chronic liver disease: a randomized, double-blind, placebo-controlled, cross-over study. J Clin Endocrinol Metab. 2002;87(6):2751\u20139.","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"990_CR28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/hep.1840110121","volume":"11","author":"TC Chang","year":"1990","unstructured":"Chang TC, Lin JJ, Yu SC, Chang TJ. Absence of growth-hormone receptor in hepatocellular carcinoma and cirrhotic liver. Hepatology. 1990;11(1):123\u20136.","journal-title":"Hepatology"},{"issue":"6","key":"990_CR29","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1530\/EJE-07-0631","volume":"157","author":"KK Ho","year":"2007","unstructured":"Ho KK. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol. 2007;157(6):695\u2013700.","journal-title":"Eur J Endocrinol."},{"issue":"1","key":"990_CR30","doi-asserted-by":"publisher","first-page":"R47","DOI":"10.1530\/EJE-18-0306","volume":"179","author":"JOL Jorgensen","year":"2018","unstructured":"Jorgensen JOL, Juul A. Growth hormone replacement therapy in adults: 30 years of personal clinical experience. Eur J Endocrinol. 2018;179(1):R47\u201356.","journal-title":"Eur J Endocrinol."},{"key":"990_CR31","unstructured":"Battelino T RM, De Schepper J, Zuckerman-Levin N, Gucev Z, S\u00e4vendahl L. A reversible albumin-binding once-weekly growth hormone (GH) treatment (somapacitan; NNC0195-0092) induces a dose-dependent IGF-I response similar to daily GH therapy in children with growth hormone deficiency (GHD). The Endocrine Society Meeting, Boston, USA 1\u20134 April, 2016. Endocr Rev. 2016;Suppl 137.2."},{"issue":"1","key":"990_CR32","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s40262-018-0662-5","volume":"58","author":"RV Juul","year":"2019","unstructured":"Juul RV, Rasmussen MH, Agerso H, Overgaard RV. Pharmacokinetics and pharmacodynamics of once-weekly somapacitan in children and adults: supporting dosing rationales with a model-based analysis of three phase I trials. Clin Pharmacokinet. 2019;58(1):63\u201375.","journal-title":"Clin Pharmacokinet."},{"key":"990_CR33","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1046\/j.1523-1755.2003.00194.x","volume":"64","author":"F Kaskel","year":"2003","unstructured":"Kaskel F. Chronic renal disease: a growing problem. Kidney Int. 2003;64:1141\u201351.","journal-title":"Kidney Int."},{"key":"990_CR34","unstructured":"Rasmussen MH, Damholt BB, Helleberg H, Bjelke M, Suresh S, Juul RV, et al. Absorption and excretion of somapacitan in healthy male subjects. In: 100th annual meeting of the endocrine society, 17\u201318 Mar 2018; Chicago, IL:SUN-569."},{"issue":"11","key":"990_CR35","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.4158\/GL-2019-0405","volume":"25","author":"KCJ Yuen","year":"2019","unstructured":"Yuen KCJ, Biller BMK, Radovick S, Carmichael JD, Jasim S, Pantalone KM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care. Endocr Pract. 2019;25(11):1191\u2013232.","journal-title":"Endocr Pract."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-021-00990-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-021-00990-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-021-00990-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T03:42:10Z","timestamp":1628048530000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-021-00990-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,23]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["990"],"URL":"https:\/\/doi.org\/10.1007\/s40262-021-00990-7","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"type":"print","value":"0312-5963"},{"type":"electronic","value":"1179-1926"}],"subject":[],"published":{"date-parts":[[2021,3,23]]},"assertion":[{"value":"16 January 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Both trials were conducted in accordance with the 1964 Helsinki Declaration and its later amendments and ICH Good Clinical Practice. The study was approved by the appropriate health authorities and an independent Ethics Committee (i.e. a review panel responsible for ensuring the protection of the rights, safety, and well-being of human subjects involved in a clinical investigation).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"These trials and publication fees (including open access) were sponsored by Novo Nordisk A\/S.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors confirm that they meet the International Committee of Medical Journal Editors (ICJME) uniform requirements for authorship and that they have contributed to critical analysis and interpretation of the data, drafting\/critically revising the article, and sharing in the final responsibility for the content of the manuscript and the decision to submit the manuscript for publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"BBD, MDB, CB, and MHR are employed by and have shares in Novo Nordisk. SLD is employed by Novo Nordisk.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all individual participants included in this study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability (Software Application or Custom Code)"}}]}}